Kamada Ltd (KMDA) 4.82 $KMDA Kamada Meets Primary

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Kamada Ltd (KMDA) 4.82 $KMDA

Kamada Meets Primary Endpoint of U.S. Phase 2 Study of Inhaled Alpha-1 Antitrypsin for the Treatment of Alpha-1 Antitrypsin Deficiency
GlobeNewswire - Tue Aug 30, 5:30AM CDT
Company's Inhaled AAT Demonstrated Significant Increase in Endothelial Lining Fluid Inhibitory Capacity
KMDA: 4.82 (-0.07)

Kamada Reports Financial Results for the Second Quarter and First Six Months of 2016
GlobeNewswire - Tue Aug 02, 5:30AM CDT
Total Revenues for First Half of 2016 Grew 20% to $33.9 Million vs. First Half of 2015
KMDA: 4.82 (-0.07)

Shire and Kamada Announce FDA Approval of Expanded Label for Self-infusion of GLASSIA for the Treatment of Emphysema Due To Severe AAT Deficiency
PR Newswire - Wed Jun 15, 6:00AM CDT
Shire plc (LSE: SHP, NASDAQ: SHPG) and Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced that the United States Food and Drug Administration (FDA) has approved an expanded label for GLASSIA [Alpha-1 Proteinase Inhibitor (Human)], marking the first treatment for adult patients with emphysema due to severe Alpha-1 Antitrypsin (AAT) Deficiency that can be self-infused at home after appropriate training.
SHPG: 187.18 (-3.04), KMDA: 4.82 (-0.07)

Kamada's Alpha-1 Antitrypsin Now Available to Treat Graft-Versus-Host Disease on myTomorrows Early Access Platform
GlobeNewswire - Wed May 25, 5:30AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, and myTomorrows, a provider of services to patients and physicians in need of diagnostic tests and drugs in development, today announced a collaboration to provide early access throughout Europe to Kamada's proprietary, highly-purified, liquid form of Alpha-1 Antitrypsin (AAT) to treat bone marrow transplant patients who develop steroid refractory Graft-Versus-Host Disease (GvHD).
KMDA: 4.82 (-0.07), BXLT: 46.02 (-0.18)

Kamada Reports 2016 First Quarter Financial Results
BusinessWire - Mon May 09, 5:30AM CDT
--Conference call begins at 8:30 a.m. Eastern time today
KMDA: 4.82 (-0.07)

Kamada to Host First Quarter Financial Results Conference Call on May 9, 2016 at 8:30 am Eastern Time
BusinessWire - Wed May 04, 7:30AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that it will release financial results for the first quarter ended March 31, 2016 prior to the open of the U.S. financial markets on Monday, May 9, 2016.
KMDA: 4.82 (-0.07)

Kamada Receives Two Milestone Payments under Strategic Agreements with Chiesi Farmaceutici and Baxalta
BusinessWire - Mon May 02, 6:00AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces receipt of two milestone payments as a result of achieving certain regulatory and sales milestones under the strategic agreements with Chiesi Farmaceutici S.p.A. and Baxalta Incorporated (NYSE: BXLT).
KMDA: 4.82 (-0.07), BXLT: 46.02 (-0.18)

Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection
BusinessWire - Wed Apr 06, 6:00AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces in the initiation of a Phase 2 clinical trial with its proprietary Alpha-1 Antitrypsin (AAT) for the prevention of lung transplant rejection. The study is being conducted in collaboration with Baxalta Incorporated (NYSE: BXLT), which has distribution rights to the Company's intravenous (IV) AAT for all indications in the U.S., Canada, Australia and New Zealand.
KMDA: 4.82 (-0.07), BXLT: 46.02 (-0.18)

Kamada Submits Marketing Authorization Application with the European Medicines Agency for its Proprietary Inhaled Alpha-1 Antitrypsin to Treat Alpha-1 Antitrypsin Deficiency
BusinessWire - Mon Mar 28, 5:30AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the submission of a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for the Company's proprietary, inhaled alpha-1 antitrypsin (AAT) therapy as a treatment for AAT deficiency (AATD). The filing was validated by the EMA.
KMDA: 4.82 (-0.07)

Kamada to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
BusinessWire - Fri Feb 05, 7:56AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today that the Company will participate at the Source Capital Group's 2016 Disruptive Growth & Healthcare Conference taking place February 10-11, 2016 in New York City. Amir London, the Company's Chief Executive Officer, will present a corporate overview on February 11th from 12:30PM to 12:55PM.
KMDA: 4.82 (-0.07)

New Strong Buy Stocks for February 4th
Zacks Equity Research - Zacks Investment Research - Thu Feb 04, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
CPTA: 15.09 (-0.10), NPTN: 14.93 (-0.32), KMDA: 4.82 (-0.07), CASY: 131.31 (-0.84), HRC: 59.31 (-0.21)

Kamada Reports 2015 Fourth Quarter and Full Year Financial Results
BusinessWire - Tue Feb 02, 6:17AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, reports financial results for the three and 12 months ended December 31, 2015.
KMDA: 4.82 (-0.07)

Cystic Fibrosis Pipeline H2 2015 Report on Drugs and Companies
PR Newswire - Thu Jan 28, 12:00AM CST
New market research titled "Cystic Fibrosis - Pipeline Review, H2 2015" is now available with ReportsnReports.com and provides an overview of the Cystic Fibrosis's therapeutic pipeline to help strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
INSM: 12.95 (-0.32), VRTX: 94.51 (-1.29), PFE: 34.80 (-0.08), GSK: 43.46 (+0.10), CNCE: 9.72 (-0.75), GLPG: 54.30 (-0.55), CYCC: 5.67 (-0.53), PTI: 14.31 (unch), SHPG: 187.18 (-3.04), PULM: 1.54 (-0.07), MRK: 62.79 (+0.08), NVLS: 6.39 (+0.08), PTCT: 8.21 (+0.52), KMDA: 4.82 (-0.07), AKTX: 9.46 (-0.05), NVS: 78.77 (-0.57)

Kamada to Host Fourth Quarter and Year End 2015 Financial Results Conference Call on February 2, 2016 at 8:30 am Eastern time
BusinessWire - Wed Jan 27, 9:41AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that it will release financial results for the three and twelve months ended December 31, 2015 prior to the open of the U.S. stock market open on Tuesday, February 2, 2016.
KMDA: 4.82 (-0.07)

Cystic Fibrosis - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/llcrjt/cystic_fibrosis) has announced the addition of the "Cystic Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cystic Fibrosis. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Actelion Ltd - Akari Therapeutics, Plc - Alaxia SAS - AlgiPharma AS - AmpliPhi Biosciences Corporation - Arcturus Therapeutics, Inc - Aridis Pharmaceuticals LLC - Bayer AG - Boehringer Ingelheim GmbH - Carolus Therapeutics, Inc. - Celtaxsys, Inc. - Chiesi Farmaceutici SpA - Cilian AG - Concert Pharmaceuticals, Inc. - Corbus pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - DiscoveryBiomed, Inc. - Errant Gene Therapeutics, LLC - Galapagos NV - GlaxoSmithKline Plc - Grifols, S.A. - Grupo Praxis Pharmaceutical SA - Horizon Pharma Plc - Insmed Incorporated - Invion Limited - JHL Biotech, Inc. - Kamada Ltd. - La Jolla Pharmaceutical Company - Lamellar Biomedical Ltd - Laurent Pharmaceuticals Inc. - (30 Others) For more information visit http://www.researchandmarkets.com/research/ll...c_fibrosis
INSM: 12.95 (-0.32), CYCC: 5.67 (-0.53), HZNP: 18.80 (-0.21), KMDA: 4.82 (-0.07), GSK: 43.46 (+0.10), AKTX: 9.46 (-0.05), APHB: 1.70 (-0.01), CNCE: 9.72 (-0.75), GLPG: 54.30 (-0.55)

Kamada Reports Further Positive Interim Data from Phase 1/2 Study of its Alpha-1 Antitrypsin to Treat Graft Versus Host Disease
BusinessWire - Wed Jan 06, 6:00AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, reports further positive interim results from a Phase 1/2 clinical trial of its proprietary alpha-1 antitrypsin (AAT) to treat steroid-refractory Graft Versus Host Disease (GvHD) which is being conducted in collaboration with Baxalta US, Inc. (NYSE: BXLT) and the Fred Hutchinson Cancer Research Center in Seattle.
KMDA: 4.82 (-0.07), BXLT: 46.02 (-0.18)

Bronchiectasis - Pipeline Review 2015
M2 - Wed Jan 06, 4:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/zh8r63/bronchiectasis) has announced the addition of the "Bronchiectasis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bronchiectasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bronchiectasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Bronchiectasis. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bronchiectasis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - Alitair Pharmaceuticals, Inc. - Bayer AG - Grifols, S.A. - Kamada Ltd. - Nostrum Pharmaceuticals, LLC - Pulmatrix, Inc. - Recipharm AB - Savara Inc. - Serendex Pharmaceuticals A/S - Therabron Therapeutics, Inc. - Vertex Pharmaceuticals Incorporated For more information visit http://www.researchandmarkets.com/research/zh...chiectasis
VRTX: 94.51 (-1.29), PULM: 1.54 (-0.07), KMDA: 4.82 (-0.07)

Kamada (KMDA) Reports Encouraging Data on Rabies Drug
Zacks Equity Research - Zacks Investment Research - Tue Dec 29, 3:40PM CST
Kamada Ltd. (KMDA) reported encouraging data from a pivotal phase II/III study on its human rabies immune globulin therapy as a post-exposure treatment for rabies.
ACHN: 8.26 (-0.10), HZNP: 18.80 (-0.21), KMDA: 4.82 (-0.07), CORT: 5.33 (-0.08)

New Strong Sell Stocks for December 23rd
Zacks Equity Research - Zacks Investment Research - Wed Dec 23, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
EVHC: 21.46 (+0.11), KRA: 36.06 (-0.52), KMDA: 4.82 (-0.07), GPS: 24.87 (-0.47), CMO: 9.92 (-0.01)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 35

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 234

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 147

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Medtronic's Bold Move to Own Carotid Market Full-Scale

Updated Category News Views 143

When a giant like Medtronic makes a move, you can bet investors take notice, and this latest acquisition is no exception. They’re reaching into their deep pockets to acquire Contego Medical, a company shaking up the world of carotid artery disease treatments. It’s a tactical strike to solidify their leadership in cardiovascular solutions. Medtronic's Bet on Innovation...

Continue Reading
Webull Faces FINRA Fine and Legal Battle Ahead

Updated Category News Views 45

Webull's Compliance Headache Webull’s been knocked around again. This time, the Financial Industry Regulatory Authority (FINRA) slapped it with a hefty $4.2 million fine. Talk about a hit to the wallet! It all boils down to them failing to roll out some basic anti-money laundering (AML) and other crucial compliance programs. This is no small oversight, and it's got...

Continue Reading
Gwen Stefani Kicks Off OCVIBE's New Concert Hall

Updated Category News Views 116

A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...

Continue Reading
Mining Equipment Market to Surge, Hitting $42.81B by 2033

Updated Category News Views 98

Forecasts on Market Growth: A Robust Climb Ahead Brace yourself because this mining equipment racket is ramping up like you wouldn't believe. Analysts are telling us the market's supposed to roar from a $28.42 billion check in 2026 to a jaw-dropping $42.81 billion come 2033. That's a 6.0% CAGR—a figure that'll catch the eye of anyone not sound asleep at the wheel....

Continue Reading
WHP Global's Japan Move: A Major Toy Market Play

Updated Category News Views 35

New Horizons for Toys"R"Us in Japan Well, folks, look who's back in the toy game with a vengeance! WHP Global is shaking hands with Pan Pacific International Holdings (PPIH) to breathe new life into Toys"R"Us across Japan. Now PPIH isn’t just any player. We're talking about Japan's fourth-largest retailer, helming giants like Don Quijote and aiming to crown itself as...

Continue Reading
Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 10

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Ballard's Q3 2026: Navigating Losses and Bold Moves

Updated Category News Views 80

Ballard’s Financial Puzzles in Q3 2026 Riding the rough waters of the third quarter in 2026, Ballard Power Systems set out its stall with some eyebrow-raising numbers. This ain't the bustling diner vibe we normally see for a thriving business. The results paint a cautious picture sprinkled with strategic shifts that demand a keen eye. GeoPura Acquisition: A Strategic...

Continue Reading

Top 5 Most Recently Viewed Articles

U.S. Industrial Production Unexpectedly Declines, Impacting Growth

Updated Category News Views 62

U.S. Industrial Production Experiences a Notable Decline The latest report reveals that U.S. industrial production has faced an unexpected decline, recorded at -0.3%. This drop highlights the ongoing struggles within the manufacturing, mining, and utility sectors. Disappointing Performance Against Expectations When comparing the -0.3% figure to a predicted decrease of...

Continue Reading
MAXHUB Partners with Microsoft to Enhance Teams Rooms Experience

Updated Category News Views 363

MAXHUB Collaborates with Microsoft to Enhance Teams In an exciting development within the tech landscape, MAXHUB is teaming up with Microsoft in an initiative aimed at improving the security and reliability of Microsoft Teams Rooms. This partnership aligns with MAXHUB's vision of leading in integrated commercial display and unified communications solutions, providing...

Continue Reading
US Dollar Strengthens While Global Markets Face Turmoil

Updated Category News Views 486

US Dollar's Rise Amid Trade Tensions In an unexpected turn of events, the US dollar has extended its gains following President Trump's announcement of new tariffs. As the global markets react to these developments, we dive into the implications for various economies and asset classes. The latest updates indicate that the 25% tariffs on imports from Canada and Mexico,...

Continue Reading
Understanding Your Rights as a Perrigo Company Shareholder

Updated Category News Views 135

Understanding Your Rights as a Perrigo Company Shareholder Shareholders of Perrigo Company plc (NYSE: PRGO) should stay informed about recent developments regarding potential securities law violations. The underlying issues stem from allegations that the company misled investors regarding its infant formula business, which has drawn significant scrutiny. Allegations...

Continue Reading
Spring Surprises: White Castle Unveils Exciting Deals Ahead

Updated Category News Views 521

Spring Promotions at White Castle As the season transforms, White Castle, the pioneering fast-food restaurant known for its Original Slider, unveils enticing deals for its loyal customers. Embracing longer days and warmer weather, the company is determined to deliver exceptional savings for all cravings this spring. Celebrating with Value-Driven Offers White Castle is...

Continue Reading